key: cord-0017540-zz6nrxb8 authors: Koh, Angela S.; Kovalik, Jean‐Paul title: Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing date: 2021-03-30 journal: ESC Heart Fail DOI: 10.1002/ehf2.13274 sha: e169610b2bf9cd5fb31b299688b3b5e76cfb64ca doc_id: 17540 cord_uid: zz6nrxb8 The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development of cardiovascular disease. These alterations, which were previously only detectable on tissue histology or corroborated on blood samples, are now detectable with modern imaging techniques. Despite the emergence of powerful new imaging tools, clinical investigation into cardiovascular ageing is challenging because ageing is a life course phenomenon involving known and unknown risk factors that play out in a dynamic fashion. Metabolomic profiling measures large numbers of metabolites with diverse chemical properties. Metabolomics has the potential to capture changes in biochemistry brought about by pathophysiologic processes as well as by normal ageing. When combined with non‐invasive cardiovascular imaging tools, metabolomics can be used to understand pathological consequences of cardiovascular ageing. This review will summarize previous metabolomics and imaging studies in cardiovascular ageing. These methods may be a clinically relevant and novel approach to identify mechanisms of cardiovascular ageing and formulate or personalize treatment strategies. Metabolomics and cardiovascular imaging have been used as a strategy to study various disease states. However, combining metabolomics and imaging to better understand cardiovascular ageing is still in its infancy, and there are minimal published data. The purpose of this review is to consider the clinical manifestations and pathologic mechanisms for cardiovascular ageing and explore how metabolomics and cardiovascular imaging can help uncover new biomarkers and mechanisms for cardiovascular ageing. Metabolomic profiling is a systems biology tool that measures large numbers of metabolites with diverse chemical properties. The metabolome differs from the genome/ transcriptome/proteome because its net output is influenced by genomic, transcriptomic, and proteomic variability. Metabolomics thus provides an integrated profile of an individual's biological status: 'the genome defines what may happen, the metabolome defines what has happened'. 1 Metabolomics profiles are also influenced by environmental exposure. [2] [3] [4] [5] [6] [7] [8] There are two main analytical approaches used in metabolomics research: targeted and untargeted. Untargeted approaches involve comprehensive analysis of all the measurable analytes in a sample. The advantage to untargeted approaches is broad coverage of potentially important analytes and/or unbiased detection of biomarkers. The disadvantage to untargeted approaches includes a workflow that makes analysing large sample sets difficult, relative quantitation of compounds, a bias towards identifying compounds with high abundance, and frequent inability to identify peaks of interest. Targeted approaches involve measuring pre-defined metabolites. Advantages to targeted approaches include use of internal standards that allows identification and absolute quantitation of analytes, including low abundance compounds as well as relatively fast workflow. The disadvantage of targeted metabolomics is that clinically important analytes can be overlooked. Metabolomics techniques have been applied to the study of human disease with novel findings that have helped our understanding of insulin resistance and diabetes, 9,10 chronic kidney disease, 11,12 depression, 13,14 and cardiovascular disease (CVD). [15] [16] [17] [18] [19] [20] [21] Cardiovascular ageing Description By the year 2030, approximately 20% of the world population will be aged 65 years or older. 22 CVD is a leading cause of death in older adults, 23 which underscores the importance of gaining a better understanding of the risk factors for CVD in older patients. The ageing process can lead to pathologic effects on the cardiovascular system, which can contribute to CVD. 23 Cardiovascular ageing refers to cardiovascular structural and functional alterations that may occur with chronological ageing and that can lead to the development of CVD. A prominent age-related change is increased stiffness of central arteries referred to as vascular ageing. 24 This results from loss of elastic fibres and increase in collagen in the large elastic arteries. 25 Arterial stiffness exposes the endothelium to greater haemodynamic loading, thus promoting endothelial activation, inflammation, and damage. 26 Increased arterial stiffness can affect ventricular relaxation by altering afterload. 27,28 Altered relaxation is associated with cellular hyperplasia and fibrosis that can ultimately worsen left ventricular diastolic function. 29 Impairments in left ventricular relaxation cause the left atrium to compensate with increases in left atrial pressure to fill the left ventricle. 30,31 Elevated left atrial pressure results in left atrial enlargement secondary to pressure and volume overload. 31 With progressive worsening of diastolic function, left atrial volume increases, giving rise to complications including atrial fibrillation and stroke. 32, 33 Large-scale cohort studies have found increased incidences of chronic heart failure, atrial fibrillation, and left ventricular hypertrophy among ageing older adults. [33] [34] [35] [36] [37] [38] [39] Several mechanisms have been proposed to be involved in the pathogenesis of cardiovascular ageing including inflammation, redox stress, and endothelial dysfunction. Inflammation is a well-established driver of ageing and ageing-related diseases. 40, 41 The inflammatory process evolved as an immunologic defence system. 42 Acute inflammation acts as a response to noxious agents such as pathogens, allergens, and toxic substances. 42 The response includes activation of immune cells to eliminate pathogens and tissue remodelling processes to repair damage. However, when the acute inflammatory response fails to resolve, more components are activated to generate a continued immune activation that leads to longer-term chronic inflammation. [43] [44] [45] Ageing is linked to dysregulation of the immune response with release of inflammatory mediators and cytokines, giving rise to a concept of age-related chronic inflammation known as 'senescent inflammation'. [46] [47] [48] This chronic low-grade inflammatory state is characterized by increased levels of circulating cytokines such as interleukin-1, interleukin-6, and tumour necrosis factor. 47, 48 In addition, age-related changes in adipose tissue content and function enhance release of pro-inflammatory cytokines. 49, 50 Inflammation is associated with changes in metabolism pathways including fattyacid-derived lipid signalling molecules. 51, 52 Dietary and gut-microbiome-derived metabolites have also been implicated in human chronic inflammatory diseases. 53 These processes promote recruitment of macrophages and T cells into tissues like myocardium and vascular walls, altering vascular structure and function, leading to arterial stiffening, atherosclerosis, and hypertension. 54 Cardiac myofibroblasts respond to cytokines with resulting changes in cell proliferation, increased expression, and activity of extracellular matrix degrading metalloproteinases. 55, 56 Over time, these lead to fibrotic cardiac remodelling and myocardial dysfunction. 57 Furthermore, cardiac fibrosis and modification contribute to increased vulnerability to cardiac arrhythmias. 58 The ageing heart shows changes in mitochondrial function, particularly in electron transport chain activity. 59, 60 Mitochondrial oxidative stress is a molecular hallmark of cardiovascular ageing. Overproduction of reactive oxygen species (ROS) in the mitochondrial electron transport chain leads to formation of highly reactive products such as peroxide that promotes cellular damage including DNA mutations. Redox stress can cause inflammation and activation of cell death pathways and may eventually contribute to cellular senescence. 61, 62 A rodent model of ageing has shown increased vascular endothelium redox stress in older animals. In this study, elevated levels of a major class of systemic bioactive lipids known as lysophosphatidylcholines (LPCs) contribute to the build-up of redox stress. 63 LPCs stimulate oxidative stress through interaction with overactive 5-lipoxygenase pathways in ageing endothelial cells. LPCs can also stimulate ROS production in human Cardiovascular ageing, metabolomics, and imaging monocyte-derived macrophages found in atherosclerotic arterial walls. 64 These ROS-stimulated macrophages go on to activate expression of urokinase-type plasminogen activator and its cell surface receptor. These observations at the cellular level may account for clinical findings. Levels of soluble urokinase-type plasminogen activator receptor have been useful for predicting risks of myocardial dysfunction in aged adults. 65 LPC has also been shown to be predictive of ageing phenotypes such as cognitive impairment and gait speed in older adults. 66, 67 Endothelial function Ageing alters the endothelium and leads to reductions in vasodilatory and antithrombotic properties while also promoting atherogenesis and thrombosis. 68, 69 The vascular changes that occur with ageing result in large artery thickening and stiffness in otherwise healthy older persons who are prone to increases in systolic and pulse pressures. These functional changes in vessel haemodynamics precede clinical disease and are associated with higher risks for developing atherosclerosis, hypertension, and stroke. 23,70-72 Brachial artery flow-mediated dilation is a standard method for assessing endothelial function in a clinical research setting. Nitric oxide supplementation has been shown to improve brachial artery flow-mediated dilation. [73] [74] [75] Among middle-aged and older adults, a 10 week trial of sodium nitrite supplementation improved endothelial function and carotid artery elasticity. 73 Metabolites such as glycerophospholipids and fatty acyls predicted improved vascular function with nitrite. 76 Interestingly, improved endothelial function occurred independently of well-known risk factors such as blood lipids, glucose, blood pressure, and body mass. These findings suggest that circulating metabolites may be helpful in gaining mechanistic insight into therapies that target endothelial function. [76] [77] [78] Dietary supplements have been shown to alter markers of redox stress, improve endothelial function, and reduce risks of chronic disease and premature ageing. 79, 80 Circulating metabolites derived from dietary polyphenols (such as blueberries) have been linked to more robust vascular flow-mediated dilatation, attenuated lipotoxicity-induced endothelial dysfunction, and may complement therapies to reduce vascular complications. 81, 82 All these suggest an important role for antioxidant and antioxidant defence for proper maintenance of endothelial cell function. These mechanistic and interventional studies have contributed to our understanding of the pathogenesis of cardiovascular ageing. Circulating metabolites have been figured prominently in many of these studies, highlighting the potential role for metabolomics in elucidating the underlying mechanisms through which ageing exerts pathological changes in the cardiovascular system. Mitochondrial function is altered in the ageing heart. 59, 60 Changes in mitochondrial function have a knock-on effect on central carbon and related pathways. Fatty acid oxidation and ketone use declines with ageing in mouse hearts. 83, 84 Reprogramming of cardiac metabolism away from fatty acid oxidation is a prominent feature of heart failure 85, 86 and may partly explain changes in heart function with ageing. The sphingolipids are a major class of lipids that play an important role in tissue signalling and are active players in diseases such as insulin resistance 87 and CVD. 88 Sphingolipid physiology changes with ageing 89 and may contribute to ageing-related decline in heart function. Declining mitochondrial function with ageing has been linked to redox state, nicotinamide adenine dinucleotide levels, and the activity of nicotinamide adenine dinucleotide-dependent deacylases known as the sirtuins. 90 The sirtuins can be activated by caloric restriction, a well-described and potent stimulus for longevity in animal models, 91 as well as resveratrol, a component of red wine. 92 Sirtuins can modulate tissue metabolic activity 93 and have been linked directly to CVD. 94 Alpha-ketoglutarate is an important central carbon metabolite and intermediate in the tricarboxylic acid cycle. Alpha-ketoglutarate has been shown to extend lifespan in worms, 95 flies, 96 and mice 97 likely through interactions with mammalian target of rapamycin and adenosine monophosphate-activated protein kinase pathways. The related tricarboxylic acid cycle intermediate succinate has been shown to accumulate during ischaemia and contributes to ROS production and damage during reperfusions. 98 Metabolomics and cardiovascular ageing Challenges Many biomarkers are in use for detecting risk of CVD as well as for monitoring response to therapy. In contrast, few biomarkers have been identified for evaluating cardiovascular ageing. Because metabolomics provides an integrated profile of an individual's biological status, it may serve as a useful tool to help us understand the complexities that surround the mechanisms of pathologic ageing. The challenge going forward will be to design methods and studies to help identify new biomarkers that can predict risk of disease and/or follow disease progression. Because ageing is a life course phenomenon, environmental exposure is an important consideration. Dynamic lifestyle 1740 A.S. Koh and J.-P. Kovalik factors such as physical activity, 99 alcohol use, and food intake can alter the course of physical ageing. 100, 101 Dietary assessment in research studies is challenging. Dietary exposures are hard to measure, and established methods such as dietary recall and food frequency questionnaires have their limitations. Similar challenges exist for quantifying other important environmental exposures including lifetime exercise patterns, bouts of acute and chronic illness, medication and other drug use, and exposure to toxins from air pollution. Given that these dynamic factors all converge upon the human metabolome, metabolomics might provide a comprehensive and integrated picture of these lifelong environmental exposures. An example of how metabolomics can detect differences in environmental exposure comes from studies of host-gut microbiome interactions. The INTERMAP study performed nuclear magnetic resonance-based urinary metabolome analyses among African-American compared with non-Hispanic white Americans, where they found higher blood pressure levels among African-American men and women. 102 They found significant differences in metabolites between the two groups that were related to differing food intakes between the groups, as well as differences in gut microbiota. Another series of studies identified trimethylamine N-oxide, a diet-derived gut microbial metabolite, as an environment-linked factor associated with increased cardiovascular and mortality risk. [103] [104] [105] Another lifestyle exposure such as exercise may also alter metabolomics profiles. 106, 107 Exercise training may produce widespread changes in energy metabolism, owing to increases in lipolysis, fatty acid oxidation, or ketogenesis. 106 Differences in exercise intensity may also result in different profiles. Under moderate-intensity exercise, for example, medium chain acylcarnitines appear to dominate, to support fat oxidation. 108 These studies highlight the importance of considering environmental exposure such as diet on cardiovascular health and strengthen the evidence base for applying metabolomics profiling onto life course exposures such as ageing. While there are community-based studies that have looked at the association between metabolomics signatures, CVD, and cardiovascular function, 109, 110 few have studied the elderly. A study by Rizza et al. 111 looked at a high-risk cohort of elderly subjects in which over half of the participants had documented coronary artery disease or stroke. Rizza et al. found a distinct signature comprising medium-chain and long-chain acylcarnitines that predicted major adverse cardiac events in this high-risk elderly population. Because these acylcarnitines are derived from fatty acid oxidation, 112 this finding suggests that mitochondrial beta-oxidation pathways are linked to increased cardiovascular risk. In an interventional study that investigated the effect of Mediterranean diet on incident CVD, participants with higher baseline concentrations of short-chain, medium-chain, and long-chain acylcarnitines had higher risk of CVD and stroke. 113 In both of these studies, metabolomics has been able to uncover new associations between disease and altered fuel metabolism pathways. The studies also show how metabolomics can be complementary to other omics technologies that have helped to unravel disease mechanisms in complex phenotypes such as heart failure, yielding biomarkers for diagnosis, prognosis, or identifying new therapeutic targets. 114 Table 1 contains a summary of human studies (selected for older age groups) that have used metabolomics to study CVD among older adults. Modern cardiovascular imaging has evolved to detect underlying disease that was previously only detectable on tissue histology or corroborated on blood samples. Disease processes commonly involved in ageing, such as inflammation, may be characterized by cardiovascular imaging (Figure 1) . For example, in the setting of acute myocardial infarction, imaging of the myocardium via absolute native T1 values on magnetic resonance or fluorodeoxyglucose positron emission tomography correctly determined level of myocardial injury as well as systemic inflammation response. 120 Mitochondrial dysfunction has been implicated as a mechanism involved in cardiovascular ageing and can be assessed with imaging tools such as hyperpolarized carbon-13 magnetic resonance spectroscopy in animals 121, 122 and phosphorus-31 spectroscopy in humans. 123 Endothelial dysfunction has traditionally been characterized by reactive hyperaemia-peripheral arterial tonometry. 124, 125 In recent times, coronary endothelial dysfunction, which leads to coronary microvascular dysfunction, has been quantitatively measured in humans by positron emission tomography. [126] [127] [128] Effects of environmental exposures such as smoking and infective agents on the cardiovascular system have also been imaged by cardiovascular imaging techniques. [129] [130] [131] Quantifying subtle functional cardiovascular changes through imaging is important in the setting of preclinical disease and may be relevant in ageing. In a large community study from MESA (Multi-Ethnic Study of Atherosclerosis), older age was associated with presence of myocardial fibrosis measured by T1 mapping on cardiac magnetic resonance imaging. 132 Cardiovascular imaging has also refined clinical phenotyping. Most cohorts define the presence of clinical disease solely by development of cardiovascular events such as acute myocardial infarction. This clinical event-driven Cardiovascular ageing, metabolomics, and imaging approach may underestimate actual disease among apparently healthy controls who may have substantial asymptomatic coronary atherosclerosis. 133 The use of non-invasive imaging techniques to identify and better classify preclinical disease will enhance potential of novel omics technologies to discover early biomarkers. . As cardiovascular ageing progresses through the stages, tools such as CV imaging and metabolomics may be useful for detecting CV changes and disease mechanisms (unidirectional dashed arrows). As cardiovascular ageing becomes clinically apparent, insights from these changes and mechanisms may continue to assist in formulating and personalizing treatment strategies (bidirectional arrows). BP, blood pressure. Another key concept is that changes should occur as a result of ageing and be viewed distinctly from concomitant risk factors that frequently accompany ageing. Pre-specified cohorts that study cardiovascular ageing independently of traditional risk factors might be necessary. Analysis of community and disease cohorts that include samples acquired prior to disease development may help to uncover novel biomarkers and pathways associated with ageing-related diseases, CVD. When used in conjunction with metabolomics techniques, non-invasive cardiovascular imaging represents a way to understand pathological consequences of ageing-related cardiovascular changes in preclinical cohorts. 134, 135 In a community-based study of older adults without clinical CVD, left atrial function assessed by cardiac magnetic resonance was used as a marker of cardiovascular ageing. 135 Left atrial function as represented by left atrial reservoir and conduit phases is known to decrease with age. 136 This study highlighted the impact of age on left atrial function, independent of traditional risk factors. Importantly, these specific left atrial functions were associated with a metabolic signature comprising medium-chain and long-chain dicarboxyl carnitines, serine, citrulline, and valine molecules, 135 highlighting the potential role of mitochondrial fuel metabolism on pathogenesis of atrial ageing. In another similar analysis, an imaging marker of arterial stiffness, known as pulse wave velocity assessed by applanation tonometry, was independently associated with a similar signature of medium-chain and long-chain dicarboxyl carnitines, independent of blood pressure. 137 These results demonstrate how preclinical imaging using established and new imaging markers, when used in conjunction with metabolomics, may be a clinically relevant and novel approach to help identify mechanisms of cardiovascular ageing. In a study that integrated whole-genome sequencing, comprehensive metabolomics, and advanced human body imaging (by echocardiography, electrocardiography, computed tomography, and magnetic resonance imaging), genomics and metabolomics association analysis identified over 5% of heterozygotes with phenotypic manifestations affecting serum metabolite levels. 138 In the near future, precision medicine strategies may require integrated methodologies to identify and predict risk of disease prior to disease manifestation. For metabolomics approaches to be clinically relevant for future applications in cardiovascular ageing, we must move beyond mere cross-sectional type analyses. Examples of how to proceed can be found in the literature. In the area of cardiovascular risk stratification, metabolomics has complemented well-established risk scoring systems to provide finer cardiovascular risk stratification, 139 efficiently predicting CVD event risk in CVD cohorts, such as patients with coronary artery disease. 88, 140 In clinical trials that target established risk factors such as hypertension and dyslipidaemia, metabolomics has been used before and after intervention to study the effects of salt-lowering 141 and novel statin therapies. 142 Lifestyle factors such as diet factors have also used metabolomics to quantify effect of diet interventions on CVD incidence. 143, 144 Physical activity, a key lifestyle factor that influences cardiovascular health, has also been shown to be associated with wide spectrum of acylcarnitines and amino acids. 145 These studies point to the role that metabolomics can play in a range of clinical settings, from observational studies, to risk stratification, to clinical trial interventions, to lifestyle-type evaluations. All of these settings are pertinent to the entire life course phenomenon of ageing. What remains to be done is for more similar type study designs to be applied onto ageing cohorts, deeply focused on measuring age as a key exposure of interest, and intervening on specific mechanisms of cardiovascular ageing. In summary, as cardiovascular ageing progresses, tools such as cardiovascular imaging and biological tools such as metabolomics may be useful for detecting early changes and also study mechanisms of progression. As cardiovascular ageing becomes clinically apparent, insights from these mechanisms may assist in formulating and/or personalizing treatment strategies (Figure 1 ). Cardiovascular ageing is a pathologic process that likely involves inflammation, redox stress, and endothelial dysfunction as well as other undefined mechanisms. Metabolomics has the potential to be a powerful tool to help unravel mechanisms of cardiovascular ageing and to identify new biomarkers that predict risk and/or monitor disease progression. Reaching these milestones will require more large-scale studies with robust cross-validation across cohorts. A.K. and J.P.K.: conceptualization and methodology. A.K. and J.P.K.: writing-original draft preparation and writingreviewing and editing. Cardiovascular ageing is a life course phenomenon that involves known and unknown risk factors that play out in a dynamic fashion. As metabolomics provides an integrated profile of biological ageing that sums up complexities of cardiovascular ageing, metabolomics may represent a novel way to detect early changes as detected by cardiovascular imaging. A combined approach involving both metabolomics and cardiovascular imaging would expand mechanistic understanding about progressive cardiovascular ageing and provide targeted treatment strategies. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden Clinical implications of the aging heart Aging-associated cardiovascular changes and their relationship to heart failure Changes in cardiovascular function with aging Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons Vascular biology of ageing-implications in hypertension Arterialventricular coupling with aging and disease The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective Geroscience: linking aging to chronic disease Inflammatory markers and onset of cardiovascular events: results from the Health ABC study Natural resolution of inflammation The effect of lipopolysaccharide on enhanced inflammatory process with age: modulation of NF-κB Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people Serum biomarkers of aging in the Brown Norway rat Redefining chronic inflammation in aging and age-related diseases: proposal of the senoinflammation concept Proinflammatory cytokines, aging, and age-related diseases Aging is associated with circulating cytokine dysregulation Fat tissue, aging, and cellular senescence Perivascular adipose tissue inflammation in vascular disease Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis Diet, metabolites, and "westernlifestyle" inflammatory diseases Inflammatory cytokines in vascular dysfunction and vascular disease Cardiac fibroblasts: at the heart of myocardial Extracellular matrix disarray as a mechanism for greater abdominal versus thoracic aortic stiffness with aging in primates Inflammatory cytokines in heart failure: mediators and markers Inflammation and the pathogenesis of atrial fibrillation Mitochondrial metabolism in aging heart Effects of aging on activities of mitochondrial electron transport chain complexes and oxidative damage in rat heart Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases Lysophosphatidylcholine enhances oxidative stress via the 5-lipoxygenase pathway in rat aorta during aging Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redoxsensitive pathway Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation Plasma phospholipids identify antecedent memory impairment in older adults Reconsidering the role of mitochondria in aging Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-κB Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study The natural history of borderline isolated systolic hypertension Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men Effects of sodium nitrite supplementation on vascular function and related small metabolite signatures in middle-aged and older adults Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk Understanding different facets of cardiovascular diseases based on model systems to human studies: a proteomic and metabolomic perspective Pharmacometabolomics of statin response Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery Significant changes in metabolic profiles after intervention with selenium and coenzyme Q 10 in an elderly population Prolonging healthy aging: longevity vitamins and proteins Anandh Babu PV. Blueberry metabolites attenuate lipotoxicity-induced endothelial dysfunction Dietary polyphenols targeting arterial stiffness: interplay of contributing mechanisms and gut microbiome-related metabolism Fatty acid oxidation by isolated perfused working hearts of aged rats Aging impairs myocardial fatty acid and ketone oxidation and modifies cardiac functional and metabolic responses to insulin in mice Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach Metabolic remodeling in hypertrophied and failing myocardium: a review Sphingolipids and phospholipids in insulin resistance and related metabolic disorders Plasma ceramides as prognostic biomarkers and their arterial and myocardial tissue correlates in acute myocardial infarction Role of sphingolipids in senescence: Cardiovascular ageing, metabolomics, and imaging 1747 implication in aging and age-related diseases Mitochondrial sirtuins and molecular mechanisms of aging Caloric restriction delays disease onset and mortality in rhesus monkeys Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation Protective effects of sirtuins in cardiovascular diseases: from bench to bedside The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR Alphaketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice Characterization of the simian adenovirus type 30 inverted terminal repeat Physical activity, sedentary leisure time, circulating metabolic markers, and risk of major vascular diseases Vegetable protein intake was inversely associated with cardiovascular mortality in a 15-year follow-up study of the general Japanese population Human metabolic phenotype diversity and its association with diet and blood pressure Dietary and urinary metabonomic factors possibly accounting for higher blood pressure of black compared with white Americans: results of International Collaborative Study on macro-/ micronutrients and blood pressure Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis Urinary levels of trimethylamine-N-oxide and incident coronary heart disease: a prospective investigation among urban Chinese adults Military training elicits marked increases in plasma metabolomic signatures of energy metabolism, lipolysis, fatty acid oxidation, and ketogenesis Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort Diastolic left ventricular function in relation to circulating metabolic biomarkers in a general population Metabolomics signature improves the prediction of cardiovascular events in elderly subjects Acylcarnitines: reflecting or inflicting insulin resistance? Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions Omics phenotyping in heart failure: the next frontier Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED trial Gut microbial diversity is associated with lower arterial stiffness in women Quantitative cardiovascular magnetic resonance: extracellular volume C-acetoacetate to β-hydroxybutyrate detects real-time mitochondrial redox state and dysfunction in heart tissue Impaired in vivo mitochondrial Krebs cycle activity after myocardial infarction assessed using hyperpolarized magnetic resonance spectroscopy Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease Endothelial dysfunction is associated with cognitive impairment of elderly cardiovascular disease patients Assessment of flowmediated dilation in humans: a methodological and physiological guideline Quantitative analysis of coronary endothelial function with generator-produced 82 Rb PET: comparison with 15 O-labelled water PET Coronary microvascular dysfunction in women with nonobstructive ischemic heart disease as assessed by positron emission tomography Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study Vasculitis changes in COVID-19 survivors with persistent symptoms: an [ 18 F]FDG-PET/CT study Long-term smoking causes more advanced coronary endothelial dysfunction in middle-aged smokers compared to young smokers Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis) Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors Age-related changes in four-dimensional CMR-derived atrioventricular junction velocities and displacements: implications for the identification of altered annular dynamics for ventricular function assessment Dissecting clinical and metabolomics associations of left atrial phasic function by cardiac magnetic resonance feature tracking Left atrial aging: a cardiac magnetic resonance feature-tracking study Metabolomic profile of arterial stiffness in aged adults Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging Metabolic predictors of incident coronary heart disease in women Development and validation of a ceramide-and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients Sodium reduction, metabolomic profiling, and cardiovascular disease risk in untreated black hypertensives Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment Characterization of metabolic responses to healthy diets and association with blood pressure: application to the Optimal Macronutrient Intake Trial for Heart Health (OmniHeart), a randomized controlled study Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED trial (Prevencion con Dieta Mediterranea) Metabolomic correlates of aerobic capacity among elderly adults We thank Dr Yen How Tan for his artistic contributions. None declared.